Vepalimomab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 08:13, 1 October 2016 (Updating {{infobox_drug}} (changes to verified fields - updated 'ChemSpiderID_Ref') per Chem/infobox_drug validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Vepalimomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetVAP-1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 ☒NcheckY (what is this?)  (verify)

Vepalimomab is a mouse monoclonal antibody developed for the treatment of inflammations. It blocks the vascular adhesion protein 1.[1]

References

  1. ^ Vainio, PJ; Kortekangas-Savolainen, O; Mikkola, JH; Jaakkola, K; Kalimo, K; Jalkanen, S; Veromaa, T (2005). "Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis". Basic & Clinical Pharmacology & Toxicology. 96 (6): 429–35. doi:10.1111/j.1742-7843.2005.pto_05.x. PMID 15910406.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Vepalimomab&oldid=742036175"